RecruitingNCT07439549
Feasibility and safety of a new buprenorphine start-up approach
About this title
Read the official source — NCT07439549Medication studyAges 19+CanadaAddiction
Understand this study
Who could participate?
Listed age limits: from 19 years.
- Listed locations
- Vancouver and 1 more locationSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 29, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 12
- Sponsor
- Pouya Azar
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Canada
- Age range
- Over 19 Years
- Official registry ID
- NCT07439549
- Official title
Show the full official title
Symptom-inhibited Naloxone Induction (SINI) to Initiate Buprenorphine/Naloxone and Buprenorphine Extended-release for Opioid Use Disorder: A Single-arm Feasibility Trial
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Vancouver
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Pouya Azar.
Does this study involve medication?
Yes. The study involves medication, including Naloxone Hydrochloride 0.4 MG/ML and Buprenorphine extended-release injection (300 mg/1.5 mL).
Who can participate?
Listed age limits: from 19 years.
Is this study still recruiting?
The registry lists this study as recruiting.
